Related Topics News - Drugs

     
 Title only   |   Print    Next page > 
     
《大行》高盛升中生製藥目標價至9.07元重申「買入」 增持正大天晴額外5%股權帶來盈利增量貢獻

2026-09-14T  
《大行》野村:中生製藥向大股東增購正大天晴5%股權 市場認可交易戰略價值惟對估值存疑

2026-09-14T  
《大行》摩通:金斯瑞配售後股價逆市上揚 重申「增持」評級

2026-09-14T  
《大行》高盛:中國CRO/CDMO行業復甦步伐明確 看好藥明系、康龍化成、凱萊英、泰格醫藥及金斯瑞

2026-09-11T  
金斯瑞生物折讓4.7%配股 淨籌逾23億元

2026-09-11T  
《大行》里昂:石藥股價急挫帶來入市機會 重申「高確信跑贏大市」評級

2026-09-10T  
石藥兩注射液獲批內地臨床

2026-09-10T  
康哲藥業狂犬雙特異性抗體「金速希」全國首批處方落地

2026-09-09T  
內地2026年國家醫保藥品目錄料11月發佈

2026-09-09T  
石藥SYH2083滴眼液獲批中國臨床試驗

2026-09-08T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.